RESUMO
P34 is an antimicrobial peptide produced by a Bacillus sp. strain isolated from the intestinal contents of a fish in the Brazilian Amazon basin with reported antibacterial activity. The aim of this work was to evaluate the peptide P34 for its in vitro antiviral properties against canine adenovirus type 2 (CAV-2), canine coronavirus (CCoV), canine distemper virus (CDV), canine parvovirus type 2 (CPV-2), equine arteritis virus (EAV), equine influenza virus (EIV), feline calicivirus (FCV) and feline herpesvirus type 1 (FHV-1). The results showed that the peptide P34 exhibited antiviral activity against EAV and FHV-1. The peptide P34 inhibited the replication of EAV by 99.9% and FHV-1 by 94.4%. Virucidal activity was detected only against EAV. When P34 and EAV were incubated for 6 h at 37 °C the viral titer reduced from 10(4.5) TCID50 to 10(2.75) TCID50, showing a percent of inhibition of 98.6%. In conclusion, our results demonstrated that P34 inhibited EAV and FHV-1 replication in infected cell cultures and it showed virucidal activity against EAV. Since there is documented resistance to the current drugs used against herpesviruses and there is no treatment for equine viral arteritis, it is advisable to search for new antiviral compounds to overcome these infections.
Assuntos
Animais , Animais Domésticos/virologia , Peptídeos Catiônicos Antimicrobianos/farmacologia , Antivirais/farmacologia , Bacillus/metabolismo , Vírus/efeitos dos fármacos , Peptídeos Catiônicos Antimicrobianos/isolamento & purificação , Antivirais/isolamento & purificação , Brasil , Bacillus/isolamento & purificação , Proteínas de Bactérias/isolamento & purificação , Proteínas de Bactérias/farmacologia , Peixes/microbiologia , Trato Gastrointestinal/microbiologia , Viabilidade Microbiana/efeitos dos fármacos , Temperatura , Fatores de Tempo , Carga Viral , Replicação Viral/efeitos dos fármacosRESUMO
O presente estudo pretende contribuir com oritentaçöes para a asistência de enfermagem a pacientes em uso de interferon, resultantes de levantamento bibliográfico e da experiência prática da autora na administraçäo desta droga em pacientes hospitalizados
Assuntos
Humanos , Masculino , Feminino , Interferons , Neoplasias/tratamento farmacológico , Cuidados de Enfermagem , Doenças Parasitárias/tratamento farmacológico , Doenças Transmissíveis/tratamento farmacológico , Vírus/efeitos dos fármacos , Leishmaniose Visceral/tratamento farmacológico , Assistência Ambulatorial , Relações Enfermeiro-PacienteRESUMO
1. SB-73, a magnesium ammonium phospholinoleate anhydride aggregate, exhibited antiviral action in vitro in the concentration range of 50 to 100 µg/ml against herpes simplex type 1, stomatitis vesicular virus, adenovirus type 5, and in vivo in the dose range of 0.7 to 1.3 mg/Kg against canine parvovirus distemper virus. 2. The lethal dose (LD50) was 2.71 ñ 1.55 g/Kg body weight in mice inoculated intraperitoneally. Oral ingestion of the aggregate up to 30 g/Kg body weight by mice had no lethal effects during the 14 days of observation. 3. In in vitro cytotoxicity experiments with fibroblasts (V-79 Chinese hamster cell line), no toxic effects were observed with SB-73 concentrations (120 µg/ml) having antiviral activity. 4. In a cellular proliferation experimental using hamster V-79 cells, we observed 72% proliferation after treatment of the cells with a high concentration (500 µg/ml) of SB-73. 5. Compound SB-73 showed no genotoxicity for human lymphocytes at concentrations of 100 µg/ml. 6. When the cytoxicity and genotoxicity of SB-73 wee compared with those of acyclovir, idoxuridine and AZT at 500µg/ml concentration the compound was found to have effects similar to those of acyclovir